NANOBIOTIX appoints senior executive from pharmaceutical industry, as Chief Operating Officer
February 07 2017 - 2:20AM
Nanobiotix appoints senior executive from
pharmaceutical industry, as Chief Operating Officer
Oncology industry veteran to oversee
operations and product commercialization
Paris,
France and Cambridge, Massachusetts, USA, February 7, 2017 -
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late
clinical-stage nanomedicine company pioneering novel approaches for
the local treatment of cancer, announced today the appointment of
Alain Dostie, a senior executive from the pharmaceutical industry,
as its Chief Operating Officer (COO).
Mr. Dostie will lead Nanobiotix's operations,
including development, manufacturing, market access and sales, for
the Company's lead product NBTXR3, which could obtain a CE Mark
approval in 2017. Previously, Mr. Dostie was the Oncology General
Manager at Novartis Germany. He joins Nanobiotix with over 25 years
of international experience in the pharmaceutical industry,
particularly in market access and oncology.
Laurent Levy, CEO of Nanobiotix, commented: "We
are thrilled to welcome Alain to the Nanobiotix team as our company
takes major strides to enter a new phase in its development. His
experience and values make Alain the perfect person to join the
team to play this crucial role."
Mr. Dostie added, "Nanobiotix is at the tipping
point of its value creation with the coming first Phase II/III
interim readout and a potential first market approval this year.
The unique, unrivaled and broadly applicable technology developed
by Nanobiotix, along with the strong and enthusiastic team,
attracted me to the Company. I am very excited to join the Company
at such an important time and contribute to its long-term
success."
Prior to joining Nanobiotix, Mr. Dostie served
as the Oncology General Manager at Novartis Pharma GmbH in Germany,
where he managed a team of several hundred of people and was
responsible for more than $1 billion in sales. Previously, he
served within the Novartis group as Oncology General Manager Canada
and Oncology Business Unit Head in the Czech Republic and Slovakia.
He also served as Executive Marketing Director and National Sales
Director positions in oncology at Novartis Pharmaceuticals Canada,
Inc., Government Affairs Manager at Merck Frosst Canada, Inc. and
various positions within Bayer Canada Inc. and Millipore Canada
during his early career. Mr. Dostie earned his Bachelor of Science
in human kinetics from the University of Guelph, in Ontario,
Canada.
-ends-
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205)
is a late clinical-stage nanomedicine company pioneering novel
approaches for the local treatment of cancer. The Company's
first-in-class, proprietary technology, NanoXray, enhances
radiotherapy energy with a view to provide a new, more efficient
treatment for cancer patients.
NanoXray products are compatible with current
radiotherapy treatments and are meant to treat potentially a wide
variety of solid tumors including soft tissue sarcoma, head and
neck cancers, liver cancers, prostate cancer, breast cancer,
glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue
sarcoma (STS), head and neck cancers, prostate cancer, and liver
cancers (primary and metastases). Additionally, head and neck
cancer and rectal cancer trials led by Nanobiotix's Taiwanese
partner, PharmaEngine, are underway in the Asia Pacific region. The
Company has filed in August 2016 for market approval (CE Marking)
in Europe for its lead product NBTXR3.
Nanobiotix is listed on the regulated market of
Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO,
Bloomberg: NANO: FP). The Company Headquarter is based in Paris,
France. Affiliate in Cambridge, United States.
Contact
Nanobiotix |
Sarah GaubertDirector, Communication & Public
Affairs+33 (0)1 40 26 07 55sarah.gaubert@nanobiotix.com
/contact@nanobiotix.com |
Noël Kurdi Director, Investor
Relations +1 (646) 241-4400 noel.kurdi@nanobiotix.com /
investors@nanobiotix.com |
Media relations |
France -
Springbok ConsultantsMarina Rosoff+33 (0)6 71 58 00
34marina@springbok.fr |
|
United States -
RooneyPartners Marion Janic +1 (212)
223-4017mjanic@rooneyco.com |
|
DisclaimerThis press release contains certain
forward-looking statements concerning Nanobiotix and its business.
Such forward-looking statements are based on assumptions that
Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking
statements will be verified, which estimates are subject to
numerous risks including the risks set forth in the update of the
reference document of Nanobiotix filed with the French Financial
Markets Authority (Autorité des Marchés Financiers) under number
D.16-0732-A01 on December 27, 2016 (a copy of which is available on
www.nanobiotix.com) and to the development of economic conditions,
financial markets and the markets in which Nanobiotix operates. The
forward-looking statements contained in this press release are also
subject to risks not yet known to Nanobiotix or not currently
considered material by Nanobiotix. The occurrence of all or part of
such risks could cause actual results, financial conditions,
performance or achievements of Nanobiotix to be materially
different from such forward-looking statements.
This press release and the information that it
contains do not constitute an offer to sell or subscribe for, or a
solicitation of an offer to purchase or subscribe for, Nanobiotix
shares in any country.
At the moment NBTXR3 does not bear a CE mark and
is not permitted to be placed on the market or put into service
until NBTXR3 has obtained a CE mark.
Nanobiotix (EU:NANO)
Historical Stock Chart
From May 2024 to Jun 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Jun 2023 to Jun 2024